Deregulation of the PI3K-AKT pathway is known to have a prominent role in various cancers, especially in the prostate.34 Here we demonstrated that BTG3 guards against the AKT-GSK3β-β-catenin signaling axis by binding and preventing AKT from localizing to the plasma membrane. The gene discussed is AKT1; the disease is cancer.